CendR Platform™ Technology
The CendR Platform™ incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer drugs to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.
CD34+ Cell Therapy Platform
Lisata’s proprietary CD34+ cell technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Through the administration of CD34+ cell therapy, the Company seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted areas.
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
LSTA1 Mechanism of Action Explanation Video
Broad, Clinical-Stage Pipeline
We aim to transform patient lives through the development of unique therapies targeting cancer and other serious diseases.
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Join Our Team
Our mission is to discover, develop and deliver innovative therapies for the treatment of advanced solid tumors and other major diseases. We can accomplish that goal through the collective efforts of talented individuals who work together to advance scientific research. We place a premium on integrity, respect, diversity, and collaboration. These values have helped us to build a growing company that offers professionally rewarding careers with the opportunity to make a meaningful contribution to patients in need.